ICLR
ICON PLC
Nasdaq: ICLR · Dublin 18, L2 · Healthcare
$151.82-0.42 (-0.28%)Closed
Market Cap$11.62B
Cash$647.3Mmost recent
Runwayprofitable
P/E (TTM)52.4EPS $2.90
52-Wk Range$80.08 – $202.92
Avg Volume1.3M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$151.82-52.5%
Pipeline
Drug candidates sponsored by ICON · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | IBI-10090 | Inflammation+4 more | Completed | 2014-10past | 4 | |
| Phase 3 | Dexamethasone | Cataract | Completed | 2016-08-16past | 1 | |
| Phase 1 | Autologous FL vaccine | Lymphoma, Follicular | Completed | 2013-10past | 1 | |
| Phase 1 | Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg) | Norovirus | Completed | 2021-10-26past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for ICLR. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.